elranatamab
pfizer
['magnetismm-3', 'elranatamab']
watch the interview with dr. summarising the results of the clinical trial magnetismm-3 he just presented at #eha2023. this trial analyses the efficacy of elranatamab in relapsed and refractory #myeloma. 
A network of highly efficient, effective and sustainable myeloma and AL amyloidosis patient organisations across Europe